Table 1

Circulating microRNA candidates that represent the development of OAC from BO

L2-IL-1β mouseHuman plasma
TissueSerum
28 wk46 wk28 wk46 wkBO (mean±SD)OAC (mean±SD)AUC (95% CI)
Group 1
miR-128-3p24.239.6144.1377.51.04±0.131.25±0.260.72 (0.49 to 0.96)
miR-328-3p37.544.4160.9314.60.84±0.131.06±0.240.70 (0.44 to 0.96)
Group 2
miR-143-3p7746.36812.1259.3123.91.36±0.691.15±0.440.51 (0.26 to 0.76
miR-144-3p198.416.5315.2101.91.47±0.71.37±1.120.58 (0.30 to 0.86)
miR-15a-5p581.7497.92235.4945.91.13±0.140.99±0.160.68 (0.44 to 0.92)
Group 3
miR-1-3p7409.47341.3575.851.40.61±0.300.51±0.250.66 (0.42 to 0.90)
miR-133b5745.75388.8777.2164.50.71±0.550.70±0.280.50 (0.24 to 0.76
7-miR combi.
(predictive index)
N. A.0.13±0.110.64±0.320.91 (0.77 to 1.00)
  • Grouping was performed based on hierarchical clustering analysis shown in figure 3A.

  • Bold value, statistically significant (p<0.05).

  • AUC, area under the receiver operating characteristic curve to discriminate patients with OAC from those without OAC; BO, Barrett’s oesophagus; IL-1β, interleukin-1β;  N. A., not applicable; OAC, oesophageal adenocarcinoma; wk, week.